Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Intrinsic Value
Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. [ Read More ]
The intrinsic value of one
Jacobio Pharmaceuticals Group Co Ltd
stock under the Base Case scenario is
2.71
HKD.
Compared to the current market price of 1.45 HKD,
Jacobio Pharmaceuticals Group Co Ltd
is
Undervalued by 46%.
Jacobio Pharmaceuticals Group Co Ltd's market capitalization is 1.1B HKD.
Jacobio Pharmaceuticals Group Co Ltd stock price is 1.45 HKD.
Jacobio Pharmaceuticals Group Co Ltd stock price (1.45 HKD) is 46% less than its Intrinsic Value (2.71 HKD).
Jacobio Pharmaceuticals Group Co Ltd. Open DCF Valuation
Jacobio Pharmaceuticals Group Co Ltd stock price (1.45 HKD) is 46% less than its Relative Value (2.71 HKD). Open Relative Valuation
Jacobio Pharmaceuticals Group Co Ltd has upside potential of 366% compared to the average analyst price target.
Open Wall St Estimates
Jacobio Pharmaceuticals Group Co Ltd has positive Gross Profit for the last twelve months.
Jacobio Pharmaceuticals Group Co Ltd's Revenue has dropped by 34% over the past 12 months.
Jacobio Pharmaceuticals Group Co Ltd's ROE (Return on Equity) has significantly increased in the last 3 years from -85% to -30%, and is approaching profitability.
Jacobio Pharmaceuticals Group Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 101% to -189%.
Jacobio Pharmaceuticals Group Co Ltd has negative Operating Income for the last twelve months.
Jacobio Pharmaceuticals Group Co Ltd has negative Net Income for the last twelve months.
Jacobio Pharmaceuticals Group Co Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -30%.
Jacobio Pharmaceuticals Group Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -189%.
Jacobio Pharmaceuticals Group Co Ltd's Revenue is forecast to grow at a rate of 49% per year over the next 3 years.
Jacobio Pharmaceuticals Group Co Ltd has negative Free Cash Flow for the last twelve months.
Jacobio Pharmaceuticals Group Co Ltd's Revenue has been falling by 49% per year for the last 3 years.
Jacobio Pharmaceuticals Group Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.18.
Jacobio Pharmaceuticals Group Co Ltd's long-term assets (1B CNY) exceed its long-term liabilties (387m CNY).
Jacobio Pharmaceuticals Group Co Ltd has negative three-year average ROE (Return on Equity): -76%. The company is not efficient at transforming stockholders' equity into net income.
Jacobio Pharmaceuticals Group Co Ltd has negative three-year average ROIC (Return on Invested Capital): -148%. The company is not efficient at using invested capital to generate operating income.
Jacobio Pharmaceuticals Group Co Ltd's short-term assets (1B CNY) exceed its short-term liabilties (205m CNY).
Jacobio Pharmaceuticals Group Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (196m CNY).
Jacobio Pharmaceuticals Group Co Ltd's Altman Z-Score is very high and is equal to 4.55.
Jacobio Pharmaceuticals Group Co Ltd doesn't generate enough operating income (-388m CNY) to safely cover interest payments on its debt (531k CNY).
Valuation Backtest
Jacobio Pharmaceuticals Group Co Ltd
Run backtest to discover the historical profit from buying and selling
Jacobio Pharmaceuticals Group Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Jacobio Pharmaceuticals Group Co Ltd
Balance Sheet Decomposition
Jacobio Pharmaceuticals Group Co Ltd
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 20.6m |
| Non-Current Assets | 292.1m |
| Long-Term Investments | 68.2m |
| PP&E | 219.6m |
| Intangibles | 1.4m |
| Other Non-Current Assets | 2.9m |
| Current Liabilities | 205.1m |
| Accounts Payable | 81.2m |
| Short-Term Debt | 73.6m |
| Other Current Liabilities | 50.3m |
| Non-Current Liabilities | 182m |
| Long-Term Debt | 122m |
| Other Non-Current Liabilities | 60m |
Earnings Waterfall
Jacobio Pharmaceuticals Group Co Ltd
|
Revenue
|
63.5m
CNY
|
|
Cost of Revenue
|
-60.3m
CNY
|
|
Gross Profit
|
3.2m
CNY
|
|
Operating Expenses
|
-390.7m
CNY
|
|
Operating Income
|
-387.5m
CNY
|
|
Other Expenses
|
28.4m
CNY
|
|
Net Income
|
-359.1m
CNY
|
Free Cash Flow Analysis
Jacobio Pharmaceuticals Group Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Jacobio Pharmaceuticals Group Co Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Jacobio Pharmaceuticals Group Co Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Jacobio Pharmaceuticals Group Co Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Jacobio Pharmaceuticals Group Co Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Jacobio Pharmaceuticals Group Co Ltd
According to Wall Street analysts, the average 1-year price target for
Jacobio Pharmaceuticals Group Co Ltd
is 6.76 HKD
with a low forecast of 5.01 HKD and a high forecast of 8.72 HKD.
Shareholder Return
Price
Jacobio Pharmaceuticals Group Co Ltd
| Average Annual Return | -21.25% |
| Standard Deviation of Annual Returns | 36.85% |
| Max Drawdown | -94% |
| Market Capitalization | 1.1B HKD |
| Shares Outstanding | 793 562 280 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Jacobio Pharmaceuticals Group Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Jacobio Pharmaceuticals Group Co Ltd
stock under the Base Case scenario is
2.71
HKD.
Compared to the current market price of 1.45 HKD,
Jacobio Pharmaceuticals Group Co Ltd
is
Undervalued by 46%.
You don't have any saved screeners yet
